SGTX - Sigilon Therapeutics GAAP EPS of -$0.44 revenue of $2.88M
- Sigilon Therapeutics press release ( NASDAQ: SGTX ): Q2 GAAP EPS of -$0.44.
- Collaboration Revenue of $2.88M (+6.7% Y/Y).
- Cash, cash equivalents and marketable securities were $88.2 million as of June 30, 2022 compared to $123.4 million as of December 31, 2021.
For further details see:
Sigilon Therapeutics GAAP EPS of -$0.44, revenue of $2.88M